Ascendis Pharma A/S
NASDAQ:ASND

Watchlist Manager
Ascendis Pharma A/S Logo
Ascendis Pharma A/S
NASDAQ:ASND
Watchlist
Price: 127.605 USD -0.62% Market Closed
Market Cap: 7.3B USD
Have any thoughts about
Ascendis Pharma A/S?
Write Note

Relative Value

The Relative Value of one ASND stock under the Base Case scenario is 156.418 USD. Compared to the current market price of 127.605 USD, Ascendis Pharma A/S is Undervalued by 18%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ASND Relative Value
Base Case
156.418 USD
Undervaluation 18%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
96
vs Industry
31
Median 3Y
60.1
Median 5Y
266.4
Industry
8.1
Forward
23.7
vs History
vs Industry
Median 3Y
-13.7
Median 5Y
-14.9
Industry
23
Forward
-16
vs History
vs Industry
Median 3Y
-13.3
Median 5Y
-18.5
Industry
23.4
vs History
vs Industry
Median 3Y
-18.3
Median 5Y
-22.6
Industry
27.3
vs History
vs Industry
0
Median 3Y
7.3
Median 5Y
7.9
Industry
2.6
vs History
96
vs Industry
26
Median 3Y
58.7
Median 5Y
242.3
Industry
8.1
Forward
25
vs History
53
vs Industry
21
Median 3Y
50.9
Median 5Y
28.3
Industry
9.6
vs History
vs Industry
Median 3Y
-12.2
Median 5Y
-16.8
Industry
4.3
Forward
-21
vs History
vs Industry
Median 3Y
-11.8
Median 5Y
-16.3
Industry
3.8
Forward
-22.1
vs History
vs Industry
Median 3Y
-12.7
Median 5Y
-18.4
Industry
6
vs History
vs Industry
Median 3Y
-12.3
Median 5Y
-17.6
Industry
3.8
vs History
74
vs Industry
13
Median 3Y
19.2
Median 5Y
22
Industry
4.8

Multiples Across Competitors

ASND Competitors Multiples
Ascendis Pharma A/S Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
DK
Ascendis Pharma A/S
NASDAQ:ASND
7.4B USD 21.9 -14.2 -22 -20.8
FR
Pharnext SCA
OTC:PNEXF
6T USD 37 222 244.5 -176 911.8 -214 827.3 -212 375.8
US
Abbvie Inc
NYSE:ABBV
309.5B USD 5.6 60.9 15.2 23.4
US
Amgen Inc
NASDAQ:AMGN
172.1B USD 5.3 40.7 18.6 35.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
127.5B USD 12 -265.7 26.9 28.2
US
Gilead Sciences Inc
NASDAQ:GILD
118.3B USD 4.2 939 10.4 10.4
US
Epizyme Inc
F:EPE
94.1B EUR 1 892.7 -483 -525.9 -511.9
AU
CSL Ltd
ASX:CSL
138.5B AUD 6.2 34.5 21.2 26.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
90.4B USD 6.5 19.4 17.9 19.9
US
Seagen Inc
F:SGT
39.3B EUR 18.2 -55.9 -60.1 -54.2
NL
argenx SE
XBRU:ARGX
33.6B EUR 18.4 -129.4 -104 -75.8
P/E Multiple
Earnings Growth
DK
Ascendis Pharma A/S
NASDAQ:ASND
Average P/E: 218.9
Negative Multiple: -14.2
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -176 911.8 N/A
US
Abbvie Inc
NYSE:ABBV
60.9
412%
US
Amgen Inc
NASDAQ:AMGN
40.7
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -265.7
42%
US
Gilead Sciences Inc
NASDAQ:GILD
939
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -483 N/A
AU
CSL Ltd
ASX:CSL
34.5
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.4
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.9 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -129.4 N/A
EV/EBITDA Multiple
EBITDA Growth
DK
Ascendis Pharma A/S
NASDAQ:ASND
Average EV/EBITDA: 18.4
Negative Multiple: -22
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -214 827.3 N/A
US
Abbvie Inc
NYSE:ABBV
15.2
28%
US
Amgen Inc
NASDAQ:AMGN
18.6
63%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.9
38%
US
Gilead Sciences Inc
NASDAQ:GILD
10.4
12%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -525.9 N/A
AU
CSL Ltd
ASX:CSL
21.2
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.9
46%
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.1 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -104 N/A
EV/EBIT Multiple
EBIT Growth
DK
Ascendis Pharma A/S
NASDAQ:ASND
Average EV/EBIT: 23.9
Negative Multiple: -20.8
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -212 375.8 N/A
US
Abbvie Inc
NYSE:ABBV
23.4
88%
US
Amgen Inc
NASDAQ:AMGN
35.3
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.2
44%
US
Gilead Sciences Inc
NASDAQ:GILD
10.4
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -511.9 N/A
AU
CSL Ltd
ASX:CSL
26.4
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.9
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.2 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -75.8 N/A

See Also

Discover More
Back to Top